<DOC>
	<DOCNO>NCT00421824</DOCNO>
	<brief_summary>Primary : - To assess complete pathological response rate strategy . Secondary : - Safety profile - To assess downstaging rate strategy . - To compare relative dose intensity oxaliplatin capecitabine strategy - To compare time progression overall survival strategy .</brief_summary>
	<brief_title>Study Neoadjuvant Chemotherapeutic Treatment ( XELOX ) Followed Chemoradiotherapy ( XELOX/RT ) Surgery Versus Chemoradiotherapy Followed Surgery Chemotherapy Patients With High Risk Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Patients rectal adenocarcinoma . Operable tumour , confirm magnetic resonance high resolution / endorectal echography , , Rectal tumour distal third , Tumours spread 5 mm perirectal fat Functional state ECOG â‰¤ 2 . Good hematological , hepatic renal function Previous pelvis radiotherapy . Previous antitumoural chemotherapy Pregnant breastfeeding woman . Childbearing woman positive pregnancy test result baseline . Menopausal woman period last 12 month . History neoplastic illness within last 5 year , except already resolve small cell skin cancer cervix cancer . Clinically significant cardiovascular disease Confirmed peripheral neuropathy . Gastrointestinal disorder bad absorption syndrome noncapable take oral medication . Blood disorder . Intercurrent noncontrolled severe infection . Patients undergone major surgery , open biopsy significant trauma lesion within previous 28 day . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>